Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE3
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
- Status
- COMPLETED
- Phase
- PHASE2
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
- Status
- RECRUITING
- Phase
- PHASE1
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
- Status
- UNKNOWN
- Phase
- PHASE2
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
- Status
- TERMINATED
- Phase
- PHASE2
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2